Abstracts tagged "Mortality"

Abstract Number: 0142 • ACR Convergence 2024
The Impact of Hospital Region on Mortality and Other Outcomes in Patients with Gout: A Two-Year Nationwide Analysis
Nidaa Rasheed¹, kHALED ABDULLAH² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Gout is characterized by chronic inflammatory arthritis caused by the deposition of monosodium urate crystals and leads to increased risk of complications, such as…
Abstract Number: 0706 • ACR Convergence 2024
Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension
Carleigh Zahn¹, Scott Visovatti², Rosemary Gedert¹, Suiyuan Huang¹, Victor Moles¹, Amber Young¹, Vallerie McLaughlin¹ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²The Ohio State University, Columbus
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of mortality in systemic sclerosis (SSc). We launched an IRB approved prospective study (NOVEL) in 2013 at…
Abstract Number: 1715 • ACR Convergence 2024
Mortality Trends for Systemic Connective Tissue Diseases Across the United States from 1999 to 2020: A CDC-Wonder Database Analysis
Naima Khan¹, Yumna Furqan², Madiha Salman¹, Eman Ali¹, Wajeeh ur Rehman³, Ibtesam Allahi⁴, Farah Yasmin⁵ and Muhammad Sohaib Asghar⁶, ¹Dow University of Health Sciences, Karachi, Pakistan, ²Texas A&M School of Medicine, Dallas, TX, ³University Health Services Hospital, Johnson, NY, ⁴Allama Iqbal Medical College, Lahore, Pakistan, ⁵Yale University School of Medicine, New Haven, CT 06511, U.S.A., New Haven, CT, ⁶AdventHealth, Sebring, FL
Background/Purpose: The mortality burden of systemic connective tissue diseases (CTDs) is expected to rise in the U.S population because of multimorbidity and ageing. The primary…
Abstract Number: 2406 • ACR Convergence 2024
Neuropsychiatric Manifestations in Indian SLE Inception Cohort for Research: Prevalence, Predictors and Outcomes
Sai Yasaswini Kommaraju¹, Liza Rajasekhar², Ashish J Mathew³, Vineeta Shobha⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Able Lawrence⁷, Bidyut Das⁸, Manish Rathi⁹, Ranjan Gupta¹⁰, Avinash Jain¹¹ and Amita Aggarwal¹², ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ²Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ³Christian Medical College, Vellore, Tamil Nadu, India, ⁴St. John’s Medical College, Bengaluru , India, Bangalore, India, ⁵Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ⁸SCB Medical College, Cuttack, Orissa, India, ⁹Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹⁰All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹¹Sawai Man Singh Hospital, Lucknow, Rajasthan, India, ¹²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) has a significant impact on morbidity associated with SLE. However, the prevalence of NPSLE has been reported variably based…
Abstract Number: 0173 • ACR Convergence 2024
Systemic Lupus Erythematosus Mortality—United States, 2018–2022
Danielle Dawson¹, Kurt Greenlund² and Kamil Barbour², ¹CDC, Atlanta, GA, ²CDC, Alpharetta, GA
Background/Purpose: Mortality due to cardiovascular disease, infections, and renal disease is elevated in people with systemic lupus erythematosus (SLE) compared with the general population, but…
Abstract Number: 0708 • ACR Convergence 2024
Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Vangala Adarsh¹, dihowm Fatma¹, Eyerusalem Akpan², Meredith Keller², Maheswari Muruganandam², N. Suzanne Emil², Frank O'Sullivan³, Roderick Fields² and wilmer sibbitt¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose: Use of high dose corticosteroids in systemic sclerosis (SSc) is considered a significant risk factor for development of scleroderma renal crisis (SRC). Intravenous (IV)…
Abstract Number: 1747 • ACR Convergence 2024
Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Parmita Das¹, Snehin Rajkumar², Eric Yen³ and Ram Singh⁴, ¹University of California Los Angeles, Saint Johns, ²UCLA David Geffen School of Medicine, Irvine, CA, ³UCLA, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic debilitating disease affecting up to 1% of the US population and has variable outcomes by race/ethnicity. We analyzed…
Abstract Number: 2443 • ACR Convergence 2024
The Clinical Phenotype of Anti-Th/To+ Patients in Systemic Sclerosis: A Case-control Study Within the European Scleroderma Trials and Research (EUSTAR) Cohort
Liala Moschetti¹, Eleonora Pedretti², Francesco Bonomi³, María Martín López⁴, Fabio Cacciapaglia⁵, cristiana sieiro santos⁶, Gianluca Moroncini⁷, Yannick Allanore⁸, Joana Caetano⁹, Brigitte Granel¹⁰, Laura Groseanu¹¹, Maria De Santis¹², Masataka Kuwana¹³, Veronica Codullo¹⁴, Mariana Pereira Silva¹⁵, Pietro Bearzi¹⁶, Laura Belloli¹⁷, Alida Taberner-Cortés¹⁸, Cristina Maglio¹⁹, Francesco Del Galdo²⁰, Corrado Campochiaro²¹, Marie-Elise Truchetet²², Giovanna Cuomo²³, Magda Parvu²⁴, Florenzo Iannone²⁵, Patricia Carreira²⁶, Serena Guiducci²⁷, Franco Franceschini¹, Paolo Airò¹ and Maria-Grazia Lazzaroni¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia; Italy, Brescia, Italy, ³Division of Rheumatology, Scleroderma Unit, University of Florence, AOU Careggi Firenze; Italy, Firenze, Italy, ⁴General University Hospital of Ciudad Real, Ciudad de México, Spain, ⁵Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ⁶Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁷Marche Polytechnic University, Ancona, Italy, ⁸Rheumatology department, Université Paris Cité, Cochin Hospital of Paris; France, Paris, France, ⁹Systemic Autoimmune Diseases Unit, Fernando Fonseca Hospital, Amadora; Portugal, Amadora, Portugal, ¹⁰Service de Médecine Interne Hôpital Nord de Marseille; France, Marseille, France, ¹¹Spitalul Sfanta Maria, Bucharest, Romania, ¹²Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital and Biomedical Sciences, Hu-manitas University, Milan; Italy, Milan, Italy, ¹³Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁴Unit of Rheumatology, San Matteo Hospital, Pavia, Italy, ¹⁵Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa; Portugal, Lisboa, Portugal, ¹⁶Immunorheumatology Unit, Università Campus Bio-Medico University of Roma; Italy, Roma, Italy, ¹⁷Niguarda Hospital, Milan, Milan, Italy, ¹⁸Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁹University of Gothenburg, Gothenburg, Sweden, ²⁰University of Leeds, Leeds, United Kingdom, ²¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²²Bordeaux University Hospital, Bordeaux, France, ²³Università degli studi della Campania Luigi Vanvitelli, Napoli, Italy, ²⁴Colentina Clinical Hospital, Rheumatology Department, Bucharest; Romania, Bucharest, Romania, ²⁵Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²⁶Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ²⁷Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Background/Purpose: To evaluate clinical associations of anti-Th/To antibodies in SSc patients in a multicentre international cohort, focusing on interstitial lung disease (ILD), pulmonary arterial hypertension…
Abstract Number: 0202 • ACR Convergence 2024
Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei¹, Hui Zhao¹, Suja Rajan³, Heather Lin¹ and Sharon Giordano¹, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson, Houston, TX, ³The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
Abstract Number: 0717 • ACR Convergence 2024
Associations Between Calendar Time and Age at Diagnosis with Mortality in a National Cohort of Veterans with ANCA-Associated Vasculitis from 2001-2020
Jennifer Hanberg¹, Svetlana Eden², Amy Anderson-Mellies², Suman Kundu², Matthew Freiberg², Zachary Wallace³ and Evelyn Hsieh⁴, and the Veterans Aging Cohort Study Project Team, ¹Brigham and Women's Hospital, Boston, MA, ²Vanderbilt University Medical Center and Tennessee Valley VA, Nashville, TN, ³Massachusetts General Hospital, Newton, MA, ⁴Yale School of Medicine / VA Connecticut Healthcare System, West Haven, Connecticut, New Haven, CT
Background/Purpose: It is not clear whether advances in ANCA-associated vasculitis (AAV) management between 2001-2020 have translated to improvement in population-level outcomes, including among older adults.…
Abstract Number: 1908 • ACR Convergence 2024
Male Sex, Medical Comorbidity and Post-procedure Complications Are Associated with Higher In-hospital Mortality After Primary Total Knee Arthroplasty for Osteoarthritis
Sumanth Chandrupatla¹, Kranti Rumalla² and Jasvinder Singh³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Baylor College of Medicine, Birmingham, AL
Background/Purpose: We aimed to assess whether sex, comorbidity and postoperative complications are associated with in-patient mortality after primary total knee arthroplasty (TKA) for osteoarthritis (OA).Methods:…
Abstract Number: 2454 • ACR Convergence 2024
Age-Adjusted Mortality Rate Trends in Systemic Sclerosis in the United States from 1999 to 2020
Ansaam Daoud¹, Loai Dweik², Muhammad Shamim³, Haseeb Chaudhary⁴ and Omer Pamuk⁵, ¹Case Western Reserve University/University Hospitals, Akron, OH, ²Cleveland Clinic Akron General Internal Medicine, Akron, OH, ³University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ⁴Case Western Reserve University, Westlake, OH, ⁵University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Of all rheumatic diseases, systemic sclerosis (SSc) has the highest disease-specific mortality, with a higher mortality risk than the general population. North America has…
Abstract Number: 0333 • ACR Convergence 2024
Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
shiri keret¹, Raisa Silva², Irada Choudhuri², Eugenia Gkiaouraki³, Tanya Chandra⁴, Nantakarn Pongtarakulpanit⁵, shreya Sriram³, silvia Martinez Laverde³, Dana Ascherman³, Siamak Mogahadam⁵, Chester Oddis⁵ and Rohit Aggarwal⁶, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Lung involvement is the most common and severe extra-muscular manifestation of Idiopathic Inflammatory Myopathies (IIM). Early identification of patients at risk for lung transplant…
Abstract Number: 0733 • ACR Convergence 2024
Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)
Sai Shanmukha Sreeram Pannala¹, fares Saliba², Medha Rajamanuri³ and Veena Katikineni⁴, ¹Staten Island University Hospital, Northwell Health, staten island, new york city, NY, ²Staten Island University Hospital, Staten Island, NY, ³Southern Illinois University School of Medicine, Springfield, IL, ⁴Providence, Victorville, CA
Background/Purpose: Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a heterogeneous group of rare autoimmune conditions characterized by inflammation of blood vessels, leading to various clinical…
Abstract Number: 1995 • ACR Convergence 2024
Use of Abatacept for the Treatment of Severe Immune-related Adverse Events from Immune Checkpoint Inhibitors for Cancer: A Case Series
Kaitlin McCarter¹, Xiaosong Wang², Senada Arabelovic¹, Nicole LeBoeuf¹, Elizabeth Buchbinder³, Lydia Gedmintas¹, Lindsey MacFarlane⁴, Deepak Rao⁵, Nancy Shadick², Elad Sharon³, Brittany Weber⁶, Anju Nohria¹, Ellen Gravallese⁷ and Jeffrey Sparks⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Dana Farber Cancer Institute, Boston, MA, ⁴Brigham and Women's Hospital, Hanover, NH, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) antagonize CTLA-4, PD-1, PD-L1, and Lag-3 to stimulate the immune system to treat cancer but may also cause immune-related adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].